An observational study in Image-Guided Biopsy - Carcinoma, Bronchogenic / Diagnosis- Outpatients, sponsored by University Hospital, Grenoble. Status unknown. Per ClinicalTrials.gov, last updated 2017-12-29.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up.
Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer.
This study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected.
This study is observational, retrospective, one center
Current progress in thoracic oncology require to be able to carry out analysis by molecular biology. So biopsies are done several times during cancer progression. But risk is high for a lung biopsy with enough sample, so a CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer can be an alternative.
In case of primary lung cancer, bone metastases biopsy can be done in initial diagnosis or follow-up. But this contribution in diagnostic (anatomopathologic an molecular biology) is poorly understood. It is demonstrated that to sample on lytic bone lesion have a failure rate lower than on calcified osseous lesion. Nevertheless, any study focus on rentability and biopsy complications of lytic bone lesion for the context of lung cancer.
this study aims to demonstrate that CT scan guide percutaneous biopsy of lytic bone lesion help to anatomopathologic diagnosis and molecular biology with a low complication rate inasmuch a lung cancer is suspected.
This study is observational, retrospective, descriptive, one-center Patient's records selection will be done by keyword search on the CHU Grenoble Alpes radiology software. Only records with bone biopsy register between January 2010 and June 2017 will be included.
66 studies on the registry are indexed under Carcinoma, Bronchogenic; 12 are open to participants now.
This study's enrollment of 80 is below the median of 300 across 15 observational studies indexed under Carcinoma, Bronchogenic.
Browse Carcinoma, Bronchogenic studies →University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
Procedure: CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer
Rentability of biopsy of lytic bone lesion in anatomopathologic analysis
Rentability of biopsy of lytic bone lesion = 100x (number of sample wich analysed by anatomopathologic /total number of biopsy of lytic bone lesion done)
Time frame: Analysis between january 2018-september 2018
Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed
Rentability of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed - =100x (number of sample wich analysed by molecular biology /total number of biopsy of lytic bone lesion sent to molecular biology analysis)
Time frame: Analysis between january 2018-september 2018
Cell quality in sample of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed
Cell quality in sample of biopsy of lytic bone lesion in molecular biology analysis inas much non small cell epidermoid lung cancer is diagnosed * average percentage of tumour cells in samples
Time frame: Analysis between january 2018-september 2018
Complication rate linked to gesture of biopsy of lytic bone lesion
Complication rate linked to gesture of biopsy of lytic bone lesion and descriptive analysis
Time frame: Analysis between january 2018-september 2018
Impact assessement of biopsy of lytic bone lesion on patient care
Modification of management of lung cancer between before biopsy and after biopsy results
Time frame: Analysis between january 2018-september 2018
No study locations are listed for this record.
Ran from Jan 2010 to primary completion in Jun 2017, 89 months.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →